Equillium Investor Relations Material

Equillium Inc. is a clinical-stage biotechnology company that focuses on developing therapeutics for severe autoimmune and inflammatory disorders that have high unmet medical needs. It leverages a deep understanding of immunobiology to create novel treatments. Equillium's pipeline includes innovative, first-in-class immunomodulatory assets targeting critical immuno-inflammatory pathways. It is headquartered in La Jolla, California, and its shares are listed on the Nasdaq.